ENTITY
BeiGene

BeiGene (6160 HK)

302
Analysis
Health CareChina
BeiGene, Ltd. operates as a commercial stage biopharmaceutical company. The Company focuses on discovery, development, and commercialization of molecularly targeted and immuno-oncology drugs for the treatment of cancer. BeiGene serves patients worldwide.
more
Refresh
bullishChina Mobile
12 Feb 2024 16:15

HK Connect SOUTHBOUND Flows (To 9 Feb 2024); Net Tech Selling STILL, Net SOE Buying, STILL

SOUTHBOUND saw net buying on this shortened week pre-CNY as stocks rebounded from the previous week's dramatic selloff. High Div SOEs were bought...

Logo
325 Views
Share
09 Feb 2024 18:50

[Blue Lotus Daily]: LKNCY/ZLAB/9995 HK/BGNE/9926 HK/1801 HK/1877 HK/ATAT/TCOM/1211 HK/LI/NIO/XPEV

​Local government plans to provide RMB600mn in travel subsidies; new regulations protect pricing of innovative drugs; Porsche's Taycan now has...

Share
28 Jan 2024 10:10

A-H Premium Weekly (Jan 26th): Haier Smart, China Tourism, Conch Cement, Tsingtao Brew, GWM

We highlight weekly changes in A-H premium for Haier Smart Home, China Tourism, Conch Cement, Tsingtao Brew, Gwmotor, China Energy Engineering,...

Logo
378 Views
Share
23 Jan 2024 12:16

Quiddity HSCEI Mar 24 Rebalance: Same Rankings; Same Questions

The index changes for HSCEI index for the March 2024 index rebal will be announced on 16th February 2024. In this insight, I have discussed the...

Share
21 Jan 2024 09:42

China Healthcare Weekly (Jan.19) - Bottom Fish A-Share?/“Style” of FDA/Pharma's Key Benchmark/3320HK

The more A-share fall, the more excited we are. CR Pharmaceutical won't go bankrupt. It's a good investment in bear mkt. FDA's approval style gives...

Logo
381 Views
Share
x